uniQure (NASDAQ:QURE) Shares Climb 6.9% – What’s Next?

uniQure N.V. (NASDAQ:QURE) shares rose 6.9% on Wednesday. The company traded as high as $26.68 and last traded at $26.21. Approximately 1,367,283 shares were traded during trading, a decline of 44% from the average session volume of 2,428,466 shares. The stock had previously closed at $24.51.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The company said its 36-month analysis, which supports its submitted Biologics License Application, showed an 80% slowing of disease progression on cUHDRS and a 67% slowing on Total Functional Capacity (TFC). The FDA has indicated that the 36-month data can serve as the primary basis for an accelerated-approval review. uniQure Announces Additional Data from Ongoing Phase I/II Studies
• Positive Sentiment: At 48 months, TFC still showed a 61% slowing of functional decline, and the company reported a dose-dependent benefit. uniQure also argued that missing data and survivor bias in the external-control group may have understated AMT-130’s effect, while maintaining that the regulatory pathway remains viable. UniQure Insists Huntington’s Drug Is Still on Track
• Neutral Sentiment: Unusually heavy options activity preceded the data release, with traders buying roughly 35,700 call options—about 488% of typical volume—indicating elevated speculative interest but not a clear directional signal.
• Negative Sentiment: The key 48-month cUHDRS endpoint showed only 44% slowing and was not statistically significant (p=0.144), compared with the stronger earlier results. Investors viewed the weaker long-term signal as a setback for confidence in AMT-130’s durability and approval prospects. UniQure’s Huntington’s Therapy Fails to Significantly Slow Disease Progression
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following the data disclosure, adding legal and reputational overhang. Reports also noted extensive insider selling over the past six months, although those transactions may include scheduled sales. uniQure Investigation Notice

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of research reports. Weiss Ratings raised shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a research report on Wednesday, July 29th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a report on Wednesday, June 17th. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 target price on shares of uniQure in a report on Tuesday. Finally, Mizuho boosted their price target on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.18.

uniQure Price Performance

The firm’s fifty day simple moving average is $44.25 and its 200-day simple moving average is $33.29. The firm has a market capitalization of $1.76 billion, a PE ratio of -6.25 and a beta of 0.94. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same quarter in the previous year, the company earned ($0.69) EPS. On average, research analysts forecast that uniQure N.V. will post -3.82 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other news, CEO Matthew Kapusta sold 21,082 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the transaction, the chief executive officer owned 519,227 shares in the company, valued at $23,448,291.32. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Large investors have recently bought and sold shares of the business. IFP Advisors Inc boosted its holdings in shares of uniQure by 39.8% during the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 791 shares during the last quarter. Mraz Amerine & Associates Inc. bought a new position in uniQure during the second quarter valued at approximately $390,000. Arizona State Retirement System boosted its holdings in uniQure by 17.7% in the second quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 1,942 shares during the last quarter. Syon Capital LLC purchased a new stake in uniQure in the second quarter worth approximately $279,000. Finally, Seven Fleet Capital Management LP bought a new stake in uniQure in the 2nd quarter worth approximately $15,254. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.